ArticleOncogene2008
Roles of cyclins A and E in induction of centrosome amplification in p53-compromised cells.
Article in Oncogene, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 49 citations in OpenAlex.
- Elucidating Differences in Early-Stage Centrosome Amplification in Primary and Immortalized Mouse Cells.International journal of molecular sciences · 2023Article
- Centrosome amplification: a quantifiable cancer cell trait with prognostic value in solid malignancies.Cancer metastasis reviews · 2021Review
- Modulation of DNA Damage Response by Sphingolipid Signaling: An Interplay that Shapes Cell Fate.International journal of molecular sciences · 2020Review
- CCNE1 Amplification as a Predictive Biomarker of Chemotherapy Resistance in Epithelial Ovarian Cancer.Diagnostics (Basel, Switzerland) · 2020Review
- Cell cycle regulation and hematologic malignancies.Blood science (Baltimore, Md.) · 2019Review
- Prognostic value of CA20, a score based on centrosome amplification-associated genes, in breast tumors.Scientific reports · 2017Article
- Cellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor Radiosensitization.International journal of molecular sciences · 2016Review
- CRKL protein overexpression enhances cell proliferation and invasion in pancreatic cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Link between DNA damage and centriole disengagement/reduplication in untransformed human cells.Journal of cellular physiology · 2014Article
- Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.International journal of oncology · 2014Article
- Disruption of clathrin-mediated trafficking causes centrosome overduplication and senescence.Traffic (Copenhagen, Denmark) · 2014Article
- Genomic instability and colon carcinogenesis: from the perspective of genes.Frontiers in oncology · 2013Article
- Cdk4 and nek2 signal binucleation and centrosome amplification in a her2+ breast cancer model.PloS one · 2013Article
- Multiplying madly: deacetylases take charge of centrosome duplication and amplification.Cell cycle (Georgetown, Tex.) · 2012Article
- Suppression of centrosome duplication and amplification by deacetylases.Cell cycle (Georgetown, Tex.) · 2012Article
- Activated ROCK II by-passes the requirement of the CDK2 activity for centrosome duplication and amplification.Oncogene · 2011Article
- Valproate inhibits colon cancer growth through cell cycle modification in vivo and in vitro.Experimental and therapeutic medicine · 2011Article
- The G1 phase Cdks regulate the centrosome cycle and mediate oncogene-dependent centrosome amplification.Cell division · 2011Article
- Cyclin A promotes S-phase entry via interaction with the replication licensing factor Mcm7.Molecular and cellular biology · 2011Article
- Abrogation of p53 function leads to metastatic transcriptome networks that typify tumor progression in human breast cancer xenografts.International journal of oncology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
Abnormal amplification of centrosomes, which occurs frequently in cancers, leads to high frequencies of mitotic defect and chromosome segregation error, profoundly affecting the rate of tumor progression. Centrosome amplification results primarily from overduplication of centrosomes, and p53 is involved in the regulation of centrosome duplication partly through controlling the activity of cyclin-dependent kinase (CDK) 2-cyclin E, a kinase complex critical for the initiation of centrosome duplication. Thus, loss or mutational inactivation of p53 leads to an increased frequency of centrosome amplification. Moreover, the status of cyclin E greatly influences the frequency of centrosome amplification in cells lacking functional p53. Here, we dissected the roles of CDK2-associating cyclins, namely cyclins E and A, in centrosome amplification in the p53-negative cells. We found that loss of cyclin E was readily compensated by cyclin A for triggering the initiation of centrosome duplication, and thus the centrosome duplication kinetics was not significantly altered in cyclin E-deficient cells. It has been shown that cells lacking functional p53, when arrested in either early S-phase or late G(2) phase, continue to reduplicate centrosomes, resulting in centrosome amplification. In cells arrested in early S phase, cyclin E, but not cyclin A, is important in centrosome amplification, whereas in the absence of cyclin E, cyclin A is important for centrosome amplification. In late G(2)-arrested cells, cyclin A is important in centrosome amplification irrespective of the cyclin E status. These findings advance our understandings of the mechanisms underlying the numeral abnormality of centrosomes and consequential genomic instability associated with loss of p53 function and aberrant expression of cyclins E and A in cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.